NZ534760A - Nutraceuticals for the treatment, protection and restoration of connective tissues - Google Patents

Nutraceuticals for the treatment, protection and restoration of connective tissues

Info

Publication number
NZ534760A
NZ534760A NZ534760A NZ53476003A NZ534760A NZ 534760 A NZ534760 A NZ 534760A NZ 534760 A NZ534760 A NZ 534760A NZ 53476003 A NZ53476003 A NZ 53476003A NZ 534760 A NZ534760 A NZ 534760A
Authority
NZ
New Zealand
Prior art keywords
tissue
gag
autolysis
polypeptide
derived
Prior art date
Application number
NZ534760A
Other languages
English (en)
Inventor
Bojang Shen
Peter Ghosh
Original Assignee
Inst Of Nutraceutical Res Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPS0112A external-priority patent/AUPS011202A0/en
Priority claimed from AUPS1054A external-priority patent/AUPS105402A0/en
Application filed by Inst Of Nutraceutical Res Pty filed Critical Inst Of Nutraceutical Res Pty
Publication of NZ534760A publication Critical patent/NZ534760A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Mobile Radio Communication Systems (AREA)
NZ534760A 2002-01-23 2003-01-23 Nutraceuticals for the treatment, protection and restoration of connective tissues NZ534760A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPS0112A AUPS011202A0 (en) 2002-01-23 2002-01-23 Nutraceuticals for the treatment, protection and restoration of connective tissues
AUPS1054A AUPS105402A0 (en) 2002-03-12 2002-03-12 Nutraceuticals for the treatment, protection and restoration of connective tissues
PCT/AU2003/000061 WO2003062279A1 (en) 2002-01-23 2003-01-23 Nutraceuticals for the treatment, protection and restoration of connective tissues

Publications (1)

Publication Number Publication Date
NZ534760A true NZ534760A (en) 2006-03-31

Family

ID=27614006

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534760A NZ534760A (en) 2002-01-23 2003-01-23 Nutraceuticals for the treatment, protection and restoration of connective tissues

Country Status (8)

Country Link
US (2) US7371820B2 (cg-RX-API-DMAC7.html)
EP (1) EP1476471A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005519914A (cg-RX-API-DMAC7.html)
AU (1) AU2003201402B2 (cg-RX-API-DMAC7.html)
CA (1) CA2474269A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ534760A (cg-RX-API-DMAC7.html)
WO (1) WO2003062279A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200506610B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
AU2003903037A0 (en) 2003-06-17 2003-07-03 Institute Of Nutraceutical Research Connective tissue derived polypeptides
WO2005067942A1 (en) * 2004-01-16 2005-07-28 Institute Of Nutraceutical Research Pty Ltd Glycosaminoglycan peptides derived from connective tissues and use thereof in the prevention of arthritis and other degenerative medical conditions
US20090319045A1 (en) 2004-10-12 2009-12-24 Truncale Katherine G Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
AU2005202062B2 (en) * 2005-01-14 2012-08-16 Institute Of Nutraceutical Research Pty Ltd Nutraceuticals for the treatment, protection, and restoration of connective tissues
JP4955944B2 (ja) * 2005-06-30 2012-06-20 丸共バイオフーズ株式会社 コンドロイチン硫酸カルシウム及びその製造方法
WO2007049987A1 (en) * 2005-10-27 2007-05-03 Savaschuk, Dmitry Alekseevich Method for producing sulphated glycosaminoglycans from a biological tissues
US20080279825A1 (en) 2007-05-10 2008-11-13 Malinin Theodore I Cartilage material
FR2918376B1 (fr) * 2007-07-04 2011-10-28 Mathieu Borge Compositions liquides ou pateuses destinees a l'apport en elements essentiels a la synthese et a la constitution des proteoglycanes, notamment pour le traitement de la degradation du cartilage
JP5143621B2 (ja) * 2008-05-08 2013-02-13 電気化学工業株式会社 哺乳動物由来の生体液試料中のヒアルロン酸の分子量分布の測定方法
FR2938762B1 (fr) * 2008-11-21 2011-02-04 Oreal Utilisation cosmetique de proteines de type dj-1 pour le traitement de la secheresse cutanee
WO2016111899A1 (en) 2015-01-05 2016-07-14 Petrucci Gary M Methods and materials for treating lung disorders
WO2016111900A1 (en) * 2015-01-05 2016-07-14 Petrucci Gary M Methods and materials for treating arthritis
WO2016178945A1 (en) * 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
KR102114892B1 (ko) 2016-01-11 2020-05-26 더 프록터 앤드 갬블 캄파니 피부 상태의 치료 방법 및 그를 위한 조성물
US10993969B2 (en) 2016-02-05 2021-05-04 Gary M. Petrucci Methods and materials for treating nerve injuries and neurological disorders
US10478531B2 (en) 2017-06-22 2019-11-19 Gary M. Petrucci Methods and materials for treating blood vessels
EP3641725A1 (en) 2017-06-23 2020-04-29 The Procter and Gamble Company Composition and method for improving the appearance of skin
US10251917B1 (en) 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
CN111235202B (zh) * 2018-11-29 2022-03-08 中国中医科学院医学实验中心 一种鹿骨蛋白质提取物及其制备方法与应用
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法
CN113603762B (zh) * 2021-08-20 2023-06-27 吉林农业大学 一种花马杂交鹿鹿角盘活性肽及其制备方法和应用
ES2956802B2 (es) * 2022-05-20 2025-10-02 Bioiberica S A U Hidrogeles para su uso en ingenieria de tejidos de la piel

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE857389A (fr) * 1977-08-02 1977-12-01 Marbex Finance Ltd Procede de preparation de chondroitines-sulfates de metaux alcalins et alcalino-terreux d'un poids moleculaire de 3000 a 6000
CA1302880C (en) 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
JP3248170B2 (ja) * 1992-12-11 2002-01-21 マルハ株式会社 コンドロイチン硫酸蛋白複合体含有食品
US6492349B1 (en) * 1993-03-31 2002-12-10 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US5364845C1 (en) 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
AU7205894A (en) * 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
EP0873128B1 (en) * 1996-01-11 2004-11-17 Jagotec Ag Oral administration of effective amounts of forms of hyaluronic acid
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US6303585B1 (en) * 1997-07-03 2001-10-16 Orquest, Inc. Cross-linked polysaccharide drug carrier
US6025327A (en) 1997-08-08 2000-02-15 Biocell Technology, Llc Hydrolyzed collagen type II and use thereof
US5922692A (en) * 1998-03-11 1999-07-13 Marino; Richard P. Concentration of glycosaminoglycans and precursors thereto in food products
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
JP3271008B2 (ja) * 1999-11-18 2002-04-02 独立行政法人産業技術総合研究所 コンドロイチン硫酸類の製造方法
DE10008896A1 (de) * 2000-02-25 2001-08-30 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Benzotriazolderivaten und Alkylnaphthalaten
JP2003532681A (ja) * 2000-05-05 2003-11-05 ジーティーシー バイオセラピューティックス インコーポレイテッド 遺伝子導入により産生されたデコリン
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2474269A1 (en) 2003-07-31
EP1476471A4 (en) 2005-03-16
US7211648B2 (en) 2007-05-01
US7371820B2 (en) 2008-05-13
AU2003201402B2 (en) 2004-12-09
ZA200406621B (en) 2005-09-28
US20050020500A1 (en) 2005-01-27
WO2003062279A1 (en) 2003-07-31
ZA200506610B (en) 2006-07-26
JP2005519914A (ja) 2005-07-07
US20060040851A1 (en) 2006-02-23
EP1476471A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
Kim et al. Purification and characterization of antioxidative peptides from bovine skin
Xie et al. Purification and characterization of four keratinases produced by Streptomyces sp. strain 16 in native human foot skin medium
WO2003039344A3 (en) Methods and compositions for correction of cardiac conduction disturbances
IL250946A0 (en) Nanobodies improved against tumor necrosis factor-alpha (tnf-alpha)
IL159903A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2004031346A3 (en) Methods and compositions concerning designed highly-specific nucleic acid binding proteins
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
Eble et al. Vipera lebetina venom contains two disintegrins inhibiting laminin-binding β1 integrins
Harrison et al. Identification of cDNAs encoding viper venom hyaluronidases: cross-generic sequence conservation of full-length and unusually short variant transcripts
Sanz et al. Molecular cloning of disintegrins from Cerastes vipera and Macrovipera lebetina transmediterranea venom gland cDNA libraries: insight into the evolution of the snake venom integrin-inhibition system
AU4653301A (en) Anti-freeze proteins, their production and use
WO1997046686A3 (en) Tumor necrosis factor-related polypeptide
JP2015218142A (ja) コラーゲンペプチド
Gajanayaka et al. Pseudoalteromonas agarivorans-derived novel ulvan lyase of polysaccharide lyase family 40: Potential application of ulvan and partially hydrolyzed products in cosmetic industry
WO2003094697A3 (en) Methods and compositions for correction of cardiac conduction disturbances
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
EP0528686B8 (en) Process for producing peptides
WO2003105784A8 (en) Compositions and methods for softening, thinning and removing hyperkeratotic tissue
Xiao et al. Fermentation of feathers with Bacillus sp. TC5 to simultaneous obtain keratinase and antioxidant-rich peptide products
MX2007004980A (es) Alanina 2,3-aminomutasas mejoradas, y polinucleotidos relacionados.
MXPA03011453A (es) Acetilacion de fragmentos de gp41.
AU2003225406A1 (en) Method of improving material comprising a pozzolanic component
JPWO2017073785A1 (ja) 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法
Roslan et al. Effect of Enzymatic Hydrolysis Time on Antioxidant Activity of Protein Hydrolysates from Sea Cucumber (Holothuria scabra).
Seiji et al. Lysosomes in mouse melanoma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed